Phase II trial of dasatinib for patients demonstrating acquired resistance to treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib (E) or gefitinib (G).

被引：0
|
作者：
Johnson, Melissa L. [1 ]
Riely, Gregory J. [1 ]
Rizvi, Naiyer A. [1 ]
Azzoli, Christopher G. [1 ]
Kris, Mark G. [1 ]
Ginsberg, Michelle S. [1 ]
Pao, William [1 ,2 ]
Miller, Vincent A. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Vanderbilt Univ, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S687 / S687
页数：1
相关论文
共 50 条
  • [21] A PHASE II STUDY OF HSP90 INHIBITOR AUY922 AND ERLOTINIB (E) IN PATIENTS (PTS) WITH EGFR-MUTANT LUNG CANCER AND ACQUIRED RESISTANCE (AR) TO EGFR TYROSINE KINASE INHIBITORS (EGFR TKIS).
    Yu, Helena A.
    Johnson, Melissa L.
    Urman, Alexandra
    Rademaker, Alfred
    Hart, Eric
    Weitner, Bing Bing
    Patel, Jyoti D.
    Kris, Mark
    Riely, Gregory
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S596 - S596
  • [22] Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Johnson, Melissa L.
    Yu, Helena A.
    Hart, Eric M.
    Weitner, Bing Bing
    Rademaker, Alfred W.
    Patel, Jyoti D.
    Kris, Mark G.
    Riely, Gregory J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) : 1666 - +
  • [23] Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)
    Zhong, Jia
    Li, Lei
    Wang, Zhijie
    Bai, Hua
    Gai, Fei
    Duan, Jianchun
    Zhao, Jun
    Zhuo, Minglei
    Wang, Yuyan
    Wang, Shuhang
    Zang, Wanchun
    Wu, Meina
    An, Tongtong
    Rao, Guanhua
    Zhu, Guanshan
    Wang, Jie
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (12) : 1766 - 1778
  • [24] Complex epidermal growth factor receptor (EGFR) mutations and responses to tyrosine kinase inhibitors (TKIs) in advanced lung adenocarcinomas
    Zhang, B.
    Wang, S.
    Qian, J.
    Yang, W.
    Qian, F.
    Lu, J.
    Zhang, Y.
    Qiao, R.
    Han, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S82 - S82
  • [25] Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).
    Reckamp, Karen L.
    Mack, Philip C.
    Ruel, Nora
    Frankel, Paul Henry
    Gitlitz, Barbara J.
    Li, Tianhong
    Koczywas, Marianna
    Gadgeel, Shirish M.
    Cristea, Mihaela C.
    Belani, Chandra Prakash
    Newman, Edward M.
    Gandara, David R.
    Lara, Primo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC)
    Arcila, M. E.
    Riely, G. J.
    Zakowski, M. F.
    Kris, M. G.
    Ladanyi, M.
    Pao, W.
    Miller, V. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: Is dose relevant?
    Seymour, L
    Goss, G
    ANNALS OF ONCOLOGY, 2005, 16 : 40 - 41
  • [28] Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences
    Lokiec, F.
    Douillard, J. -Y.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2011, 67 : S15 - S19
  • [29] Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma
    Changhui Li
    Bo Zhang
    Jindong Guo
    Fang Hu
    Wei Nie
    Xiaoxuan Zheng
    Lixin Wang
    Yuqing Lou
    Yinchen Shen
    Baohui Han
    Xueyan Zhang
    Targeted Oncology, 2019, 14 : 423 - 431
  • [30] CHARACTERISTICS OF RE-BIOPSIED NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS
    Arai, Daisuke
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Tani, Tetsuo
    Kuroda, Aoi
    Ishioka, Kota
    Ohgino, Keiko
    Sato, Takashi
    Terai, Hideki
    Ikemura, Shinnosuke
    Hamamoto, Junko
    Naoki, Katsuhiko
    Hayashi, Yuichiro
    Betsuyaku, Tomoko
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S581 - S582
12345